To Get Help Now
Click Here
 
Today's Date:

FDA Reviewing Yaz, Yasmin Blood Clot Connection

AddThis Social Bookmark Button

The Food and Drug Administration (FDA) is currently reviewing studies pointing to an increased risk of blood clots from birth control pills like Yaz and Yasmin.   Yesterday, the agency released a statement saying “The FDA is currently evaluating the conflicting results from these studies and will look at all currently available information to fully assess the risks and benefits of drospirenone-containing birth control pills,” and that it “will continue to communicate any new safety information to the public as it becomes available.”

Drospirenone is a synthetic form of progestin.  Other birth control pills that contain drospirenone that are included in the FDA’s review are: Beyaz, Gianvi, Loryna, Ocella, Safyral, Syeda, and Zarah.

The European Medicines Agency has already concluded that these types of birth control pills increase the risk of serious side effects like venous thromboembolism, and that labels should be updated to include the warning.

The official website of Yaz includes a warning that the oral contraceptive has been “associated with increased risks of several serious side effects, including blood clots, stroke, and heart attack. “

Andres. F Alonso, Esq.,  a partner in the national law firm Parker Waichman Alonso LLP, was appointed to the Plaintiff Steering Committee in a Multidistrict Litigation (MDL) pending in U.S. District Court for the Southern District of Illinois regarding Yasmin and Yaz products liability, and the thousands of lawsuits that have been filed across the nation claiming that the drospirenone oral contraceptive caused strokes, deep vein thrombosis, gallbladder disease, pulmonary emboli and blood clots.

breakinglawsuitnews.com disclaimer: This article: FDA Reviewing Yaz, Yasmin Blood Clot Connection was posted on Wednesday, June 1st, 2011 at 7:13 pm at breakinglawsuitnews.com and is filed under Defective Drug Lawsuits.

« »

Leave a Reply

You must be logged in to post a comment.